New research from The Jackson Laboratory reveals that the body’s own immune cells, while crucial for defending against disease, can also prevent tissue regeneration. The study, led by Senior Research Scientist James Godwin, also an assistant professor at the MDI Biological Laboratory in Bar Harbor, Maine, discovered that a specific subset of these cells can, conversely, protect the rebuilding process. These findings, published in npj Regenerative Medicine, alter scientific understanding of the immune system’s role in tissue repair.
The research focused on fingertip regeneration in mice, a mammalian model that, like humans, exhibits limited capacity to regrow tissues such as bone, skin, and nail. Godwin built upon his prior work which showed that macrophages, a type of innate immune cell, are vital for heart regeneration in axolotls. He noted that there has been an underappreciation of the immune system's importance in directing repair processes, with accumulating evidence suggesting it determines the success or failure of most wounds. His team then investigated adaptive immune cells, which learn to target specific threats like viruses and cancer cells.
The experimental design involved 16 genetically diverse mouse strains, some engineered to lack different immune cell types, to ensure broad applicability of conclusions. A consistent pattern emerged: when adaptive immune cells were absent, regeneration of the injured digit tip was faster and more effective. The findings indicated the immune system was not a passive bystander, but rather an 'active brake on the process.'
Researchers identified CD4+ T cells, sometimes called “helper” T cells, as key inhibitors. These cells were found to directly kill progenitor cells, which are necessary for rebuilding bone. Imaging under the microscope showed CD4+ T cells attacking progenitor cells, leading to their death and stalled regeneration. The team pinpointed interferon-gamma, an immune signaling molecule, as a primary driver of this cytotoxic activity. When CD4+ T cells were unable to produce interferon-gamma, they no longer blocked regeneration, linking the destructive behavior to a specific molecular pathway.
Godwin explained that while CD4+ T cells act as negative forces in this context, they are also the guardians of the body against cancer and viruses. This suggests a potential evolutionary trade-off, where mammals have limited regenerative capacity in exchange for robust surveillance against threats. This idea reframes the limited regenerative power of mammals not as a simple evolutionary failure, but as the price of a vigilant immune system.
However, the research also revealed that not all CD4+ T cells behave destructively. Regulatory T cells (Tregs), a subset of CD4+ T cells known for controlling immune responses, were found to protect progenitor cells from attack by other CD4+ T cells. When Tregs were removed from the experimental model, regeneration was delayed, and the immune system began damaging even uninjured bone. This suggested Tregs restrain both the attack on regenerating tissue and collateral damage to healthy structures.
The protective role of Tregs was further demonstrated in “rescue experiments.” Adding Tregs back restored regeneration. Similarly, increasing levels of RANKL, a naturally occurring molecule known to regulate bone breakdown and remodeling, also aided regeneration. Godwin noted that these findings offer new insight into immune system interaction with bone and how this balance can be disrupted by conditions like disease and aging, where Treg function and bone remodeling are known to change.
While more research is required to determine if similar mechanisms apply in human tissue, the study suggests practical strategies for regenerative medicine. Cell-based therapies, which often face challenges with transplanted cell survival, might benefit from protecting these cells from destructive immune responses. The research emphasizes that the focus should not solely be on sourcing cells, but also on keeping them alive within the body once the immune system notices them. Godwin expressed optimism about future possibilities, stating that in the future, if someone had a severe injury, targeted immunotherapy might be used to temporarily shift the immune system to support regeneration while suppressing interference. He cautioned that therapies are not yet ready, but identifying the necessary changes is a crucial step forward. The study’s central message is that mammalian regeneration may be shaped by a negotiable immune balance rather than an immutable biological limit, implying a potential to adjust this balance.
